CURRICULUM VITAE
Sumana Devata MD
Sumana Devata MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Milwaukee VA Medical Center
Department of Medicine
Division of Hematology and Oncology - Medicine
Milwaukee VA Medical Center
OFFICE ADDRESS: |
Froedtert Hospital |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
Phone: 414-805-0510 |
Email: sdevata@mcw.edu |
EDUCATION: |
08/1997 - 05/2001 BA in Biology, Cum Laude
Major: Biology; Minor: Business Administration, Boston University College of Arts and Sciences, Boston, MA |
07/2004 - 06/2008 Doctor of Medicine, Loyola University Stritch School of Medicine, Maywood, IL |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
06/2008 - 06/2009 Medical Intern, Medicine, Medical College of Wisconsin, Milwaukee, WI |
07/2009 - 06/2011 Resident Physician, Medicine, Medical College of Wisconsin, Milwaukee, WI |
07/2011 - 06/2012 Chief Resident/Instructor, Medicine, Medical College of Wisconsin, Milwaukee, WI |
07/2012 - 06/2015 Fellow, Internal Medicine, Hematology/Oncology, University of Michigan Health System, Ann Arbor, MI |
FACULTY APPOINTMENTS: |
07/2015 - 02/2020 Clinical Assistant Professor, Internal Medicine, Hematology/Oncology, University of Michigan Health System, Ann Arbor, MI |
09/2015 - 02/2020 Clinical Assistant Professor, Internal Medicine, Hematology/Oncology, VA Ann Arbor Healthcare System, Ann Arbor, MI |
06/2020 - Present Associate Professor, Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI |
06/2020 - 07/2021 Associate Professor, Associate Section Chief, Medicine, Hematology/Oncology, Clement J. Zablocki VA Hospital, Milwaukee, WI |
07/2021 - Present Associate Professor, Section Chief, Hematology/Oncology, Milwaukee VA Medical Center, Milwaukee, WI |
ADMINISTRATIVE APPOINTMENTS: |
06/2000 - 08/2000 Coordinator/Intern in Logistics Department, Sydney Organizing Committee for the Olympic Games, Sydney, Australia |
09/2000 - 06/2001 Intern, Cancer Genetics, Inc., Cambridge, MA |
07/2001 - 05/2004 Marketing Coordinator, Product Manager, Cancer Genetics, Inc., Cambridge, MA |
06/2004 - 06/2005 Consultant, Cancer Genetics, Inc., Cambridge, MA |
RESEARCH ADMINISTRATIVE APPOINTMENTS: |
06/1996 - 08/1996 Research Assistant, Pathology, VA Hospital, Hines, IL |
06/1997 - 08/1997 Research Assistant, Pathology, VA Hospital, Hines, IL |
05/1999 - 09/1999 Student Researcher, Vision and Perception Lab, Boston University, Boston, MA |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine | 08/2011 | 08/2021 |
Medical Oncology | 10/2015 | 10/2025 |
Hematology | 10/2016 | 10/2026 |
Licensure | Number | Issue Date | Expiration |
Temporary Education Training Permit | State of Wisconin | 2009 | 2010 |
Medical License | 54086-20 | 2010 | 2025 |
Federal DEA | 2010 | 2025 | |
Educational Limited Medical License | 4301100211 | 2012 | 2015 |
Medical License | 2015 | 2021 | |
Controlled Substance License | 5315071617 | 2015 | 2020 |
AWARDS AND HONORS: |
2009 Top Ten Teaching Resident
Selected as one of the top ten teaching residents out of 120 residents, Medical College of Wisconsin |
2010 Recognition by the Resident Evaluation Committee; Top 5% of residents recognized for performance and service by the Evaluation Committee, Medical College of Wisconsin |
2010 - 2011 Outstanding Medical Student Teacher Award, Medical College of Wisconsin |
10/2013 Competitively selected to participate in the Hemostasis & Thrombosis Research Society’s Hematology Fellows Consortium, Isle of Palms, SC |
2013 - 2018 Making a Difference Award; Recognized by a patient or staff for care provided, Various years, University of Michigan Health System |
06/2014 Hematology/Oncology Fellowship Program Outstanding Clinical Research Paper Award, University of Michigan Health System |
07/2014 Competitively selected to participate in the ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, CO |
07/2014 - 07/2015 Pardee Fellow, Hematology/Oncology Fellowship Program, University of Michigan Health System |
08/2014 Competitively selected to participate in the ASH Clinical Research Training Institute Workshop, La Jolla, CA |
10/2014 Abstract Achievement Award for abstract “The Absolute Lymphocyte to Monocyte Ratio at Diagnosis Further Stratifies Survival Based on Cell of Origin in Diffuse Large B-Cell Lymphoma.”, American Society of Hematology |
06/2017 “Best Lecture of the Year”, awarded by the Fellows for a lecture given on Hodgkin Lymphoma |
01/2023 Competitively selected to participate in the Women’s Leadership Learning Collaborative. Sponsored by the Center for the Advancement of Women in Science and Medicine., Medical College of Wisconsin |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
2012 - Present American Society of Clinical Oncology |
2012 - Present American Society of Hematology |
2013 - 2020 Michigan Society of Hematology and Oncology |
2014 - Present Society of Hematologic Oncology |
2020 - Present Wisconsin Association of Hematology and Oncology (WAHO) |
2020 - Present Association of VA Hematology/Oncology (AVAHO) |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
12/2005 - 04/2006 Co-House Captain, Rebuilding Together (Led thirty medical students in renovating a home in an underserved area of Chicago.), Rebuilding Together, Inc., Chicago, IL |
07/2008 - 06/2011 Elected Resident Member, Medical College of Wisconsin Housestaff Representative Council |
06/2009 - 06/2010 Elected Resident Member, Medical College of Wisconsin Graduate Medical Education Council |
09/2010 - 06/2012 Resident and Chief Resident Member, Medical College of Wisconsin Resident Curriculum Committee |
07/2012 - 02/2020 Member, Program Evaluation Committee, Hematology/Oncology Fellowship Program, University of Michigan Rogel Cancer Center |
05/2017 - 11/2017 Physician Representative, VIA Oncology Committee, University of Michigan Rogel Cancer Center |
10/2017 - 02/2020 Representative, National VIA Medical Oncology Committee; Via Pathways Lymphoma Committee, University of Michigan |
01/2018 - 02/2020 Member, Protocol Review Committee, University of Michigan Rogel Cancer Center |
01/2019 - 02/2020 Member;Key Clinical Faculty, Hematology/Oncology Fellowship Program, University of Michigan Rogel Cancer Center |
06/2020 - Present NCTN Liaison, MCW Lymphoma DOT and Milwaukee VA Medical Center, Medical College of Wisconsin and Milwaukee VA Medical Center |
07/2020 - Present Member, Program Evaluation Committee, Hematology/Oncology Fellowship Program - Medical College of Wisconsin |
07/2020 - Present Alternate Member, Milwaukee VA Cancer Committee, Survivorship Program Director/Coordinator |
2020 - Present Interviewer, Hematology/Oncology Fellowship Applicant interviewer, Medical College of Wisconsin |
2020 - 2022 Physician Member, EPIC Advisory Group for the Medical College of Wisconsin |
2020 Reviewer, Hematology/Oncology Fellowship Applicant Reviewer, Medical College of Wisconsin |
2021 - Present Member, Milwaukee VA Blood Utilization Committee, Milwaukee VA |
2021 - Present Member, Veterans Administration VISN 12 Hematology/Oncology specialty care lead for Hematology/Oncology, Milwaukee VA Health System, Milwaukee, WI |
2022 ASH Abstract Reviewer (Category 623: Mantle Cell, Follicular, and Other Indolent B-cell Lymphomas: Clinical and Epidemiological), 64th ASH Annual Meeting and Exposition, New Orleans, LA |
2022 ASH Oral Session Moderator, Follicular Lymphoma at the 64th ASH Annual Meeting and Exposition, New Orleans, LA |
01/2023 - 01/2024 Participant, MCW Woman’s Leadership Learning Collaborative (WLLC), Medical College of Wisconsin, Milwaukee, WI |
2023 - Present Co-Developed and voting member, VA VISN 12 Hematology/Oncology Committee as part of VHA Directive 1415. Milwaukee VA Health System, Milwaukee, WI |
03/2024 Co-Director, 2024 Controversies in Hematologic Malignancies Symposium, Hosted by the Medical College of Wisconsin. Saint Kate Art Hotel, Milwaukee, Wisconsin |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
National |
Secondary CNS Lymphoma: Risk Factors and Treatment Options, Hematology/Oncology Division Conference, 03/2016 |
Non-Hodgkin Lymphoma II: High Grade Lymphomas, Hematology/Oncology Fellows Conference, 09/2016 |
Discussant, Progress from the Field, Advance Care Planning, MOQC American College of Physicians Collaborative Meeting, Ann Arbor, MI, 10/2016 |
Immunosuppression Associated Lymphoproliferative Disorders, Hematology/Oncology Division Conference, 11/2016 |
Group Leader, Hematology Second Year Medical School Small Group Session, University of Michigan Medical School, Ann Arbor, MI, 2016 - 2019 |
Hodgkin Lymphoma, Hematology/Oncology Fellows Conference, 05/2017 |
Rituximab and Late Onset Neutropenia, Hematology/Oncology Division Conference, 06/2017 |
Immunosuppression Associated Lymphoproliferative Disorders, Hematopathology Educational Conference, 11/2017 |
Non-Hodgkin Lymphoma II: High Grade Lymphomas, Hematology/Oncology Fellows Conference, 01/2018 |
Expert Speaker, "Ask the Doctor: Updates on Lymphoma Treatment and Treatment Options", Lymphoma Research Foundation, Ann Arbor, MI, 05/2018 |
Expert Speaker, "Highlighted Presentation on Diffuse Large B-Cell Lymphoma and Treatment based on Molecular Subtypes", Inaugural Lymphoma Symposium with the University of Michigan and Karmanos Cancer Institute, Dearborn, MI, 09/2018 |
Hodgkin Lymphoma, Hematology/Oncology Fellows Conference, 10/2018 |
Expert speaker, "Aggressive Lymphoma", MSHO: Interpreting Clinical Data: Highlights from ASH 2018, Dearborn, MI, 01/2019 |
Expert Speaker: "Diffuse Large B-Cell Lymphoma", Lymphoma Symposium with the University of Michigan and Karmanos Cancer Institute, Dearborn, MI, 09/2019 |
Primary Mediastinal B-Cell Lymphoma and FDC Sarcoma in association with Castleman Disease, Faculty Moderator: Translational Pathology Course Group Discussion, 11/2019 |
Aggressive Lymphomas, Hematology/Oncology Fellows Conference, 01/2021 |
Expert speaker, “Updates in the Treatment of Lymphoma”, Wellness House, Hinsdale, IL, 01/2021 |
Aggressive Lymphomas, Hematology/Oncology Fellows Conference, 03/2022 |
Expert speaker, “Hot Topics in Blood Cancers.”, Wellness House, Hinsdale, IL, 11/2022 |
Aggressive Lymphomas, Hematology/Oncology Fellows Conference, 04/2023 |
Local |
Expert Speaker, "Non-Hodgkin's Lymphoma", The Word on Medicine Radio Program, Medical College of Wisconsin, Milwaukee, WI, 09/2020 |
Expert speaker, “Cancer Care at the VA.”, The Word on Medicine Radio Program, Medical College of Wisconsin, Milwaukee, WI, 03/2021 |
Expert speaker, “Supportive Care, Being a Doctor for the Whole Patient.”, The Word on Medicine Radio Program, Medical College of Wisconsin, Milwaukee, WI, 04/2021 |
Expert speaker, “Treatment Updates for Relapsed/Refractory DLBCL.”, 10th Annual Controversies in Hematologic Malignancies, Medical College of Wisconsin, Milwaukee, WI, 04/2021 |
Expert speaker, “Advances in the Treatment of Relapsed/Refractory DLBCL.”, OncLive Sate of the Science Summit: Leukemia/Lymphoma, Milwaukee, WI, 06/2022 |
Expert speaker, “Frontline Treatment of Patients with DLBCL.”, 2023 Wisconsin Multiple Myeloma and Lymphoma Summit, Milwaukee, WI, 08/2023 |
Expert Speaker, “Frontline DLBCL.”, Controversies in Hematologic Malignancies Symposium 2024, Milwaukee, WI, 03/2024 |
RESEARCH & CLINICAL INTERESTS: |
1. Developing novel therapeutics through translational clinical trials in Hodgkin and Non- Hodgkin Lymphoma
2. Supporting and building a clinical trials program and cancer program for our Veterans at the VA Medical Center.
|
BIBLIOGRAPHY |
Books, Chapters, and Reviews |
1. Devata S, Chugh R. “Desmoid Tumors: A Comprehensive Review of the Evolving Biology, Unpredictable Behavior and Myriad of Management Options.” Hematology/Oncology Clinics of North America, ed. Andrew J. Wagner. Philadelphia: Elsevier, 2013; 27(5): 989-1005. PMID: 24093172 |
2. Devata S, Magenau J, Bixby D. “Myelodysplastic Syndrome.” Tumor Board Review: Guidelines and Case Reviews in Oncology, Second edition. Eds. Todd RF, Cooney KA, Hayes TG, Pritchett Mims M, Worden F. New York: Demos Medical, 2015: 396-403.
ISBN: 978-62070-060-0
|
3. Devata S, Wilcox R. “Peripheral T-Cell Lymphomas.” Oncology Boards Flash Review 2nd Edition. Eds. Worden FP, Khoriaty RN, Cobain EF, Pearson AT. United States of America: Springer Publishing Company, 2017: 89-95. IBSN: 9781620701157 |
4. Devata S, Wilcox RA. “T-cell and NK-cell Neoplasms.” Hematology Board Review. Eds. Worden FP, Khoriaty RN, Cooney KA, Deininger MW. United States of America: Springer Publishing Company, 2018: 273-281. IBSN: 9780826137838 |
5. Devata S. “Thrombocytopenia; Thrombocytosis, Anemia, Polycythemia; Leukocytosis, Eosinophilia; Lymphadenopathy; Metastatic Neoplasms.” The Saint-Chopra Guide to Inpatient Medicine 4th edition. Eds. Sanjay Saint and Vineet Chopra. United States of America: Oxford University Press, 2019: 329-356 and 373-376. IBSN: 9780190862800. |
Abstracts |
1. Devata S. “The War Came Home: The Gulf War Syndrome,” Mysore Medical College Reunion Scientific Meeting Speaker, “Environment and Health Symposium,” December 26-28, 1996, Costa Rica |
2. Devata S, Pfeifer K. Doubly Unexpected. Poster presentation at the American College of Physicians Annual Meeting, April 22-24, 2010, Toronto, Canada |
3. Carthan K, Devata S, Pfeifer K. Always Dangerous, but Often Overlooked. Poster presentation at the Society of General Internal Medicine, 33rd Annual Meeting, April 28-May 1, 2010, Minneapolis, MN. |
4. Devata S, Farrington L, Pfeifer K. Thick Blood: Polycythemia Vera and its Manifestations. Poster presentation at the Society of General Internal Medicine, 33rd Annual Meeting, April 28-May 1, 2010, Minneapolis, MN. |
5. Devata S, Pfeifer K. Doubly Unexpected: Down Syndrome and Male Breast Cancer. Poster presentation at the Society of General Internal Medicine, 33rd Annual Meeting, April 28-May 1, 2010, Minneapolis, MN. |
6. Devata S, Hari P. Henoch-Schönlein purpura: a paraneoplastic manifestation. Poster presentation at the American College of Physicians Annual Meeting, April 7-11, 2011, San Diego, CA. |
7. Devata S, Cheng Y, Pfeifer K. An Unexpected Presentation of Breast Cancer. Poster presentation at the Society of General Internal Medicine, 34th Annual Meeting, May 4-7, 2011, Phoenix, AZ. |
8. Devata S, Hari P, Pfeifer K. Henoch-Schönlein purpura associated with IgA plasma cell dyscrasias. Poster presentation at the Society of General Internal Medicine, 34th Annual Meeting, May 4-7, 2011, Phoenix, AZ. |
9. Cornell RF, Singh V, Devata S, Saad AA, Palmer JM, Hari P. Myeloma (MM) after autologous transplant (AutoHCT): Biochemical versus clinical progression. JCO 29(15)supplement, e18575. |
10. Wakefield TW, Sood SL, Devata S. “How to Properly Design and Interpret Clinical Data.” Presented by Dr. Thomas Wakefield. VEITH Symposium 2014, November 18-22, 2014, New York, NY. |
11. Devata S, Herrman N, Briski R, Keyoumarsi F, Boyer D, Lim M, Bailey N, Wilcox RA. The Absolute Lymphocyte to Monocyte ratio at Diagnosis Further Stratifies Survival Based on Cell of Origin in Diffuse Large-B-Cell Lymphoma. Poster presentation at the 56th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2014, San Francisco, CA. |
12. Mogasala N, Devata S, Perissinotti A, Bixby D. Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not Be Followed. Poster presentation at the 56th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2014, San Francisco, CA |
13. Devata S, Herrman N, Briski R, Keyoumarsi F, Boyer D, Lim M, Bailey N, Wilcox RA. The Absolute Lymphocyte to Monocyte ratio at Diagnosis Further Stratifies Survival Based on Cell of Origin in Diffuse Large-B-Cell Lymphoma. Poster presentation at the 23rd Annual Department of Internal Medicine Research Symposium, May 28-29, 2015, Ann Arbor, MI. |
14. Grivas P*, Devata S*, Khoriaty R, et al. “Low-cost stepped intervention to increase influenza vaccination rates at a Comprehensive Cancer Center. J Clin Oncol (Meeting Abstracts) 2015; 33:e17654. *Designates co-first authors. |
15. Wilfong JM, Kadakia KC, Devata S, Radojcic V. Improving durable power of attorney completion rates within an academic cancer center. J Clin Oncol (Meeting Abstracts) 2015; 33:e17672. |
16. Devata S, Parkin B, Khan M, Sood SL. Molecular markers and venous thromboembolism (VTE) in acute myelogenous leukemia (AML). Poster presentation at the Society of Hematologic Oncology 2015 Annual Meeting, September 16-19, 2015, Houston, TX. |
17. Devata S, Sood SL, Hemmer MV, Flanner H, Kramer W, Nietubicz C, Hawley A, Angelini DE, Myers DD, Blackburn S, Froehlich J, Wakefield TW, Magnani JL, Thackray HM. First in Human Phase 1 Single Dose Escalation Studies of the ESelectin Antagonist GMI1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile. Poster presentation at the 57th American Society of Hematology Annual Meeting and Exposition, December 5-8, 2015, Orlando, FL. |
18. Wakefield TW, Sood SL, Devata S. “How to Properly Design and Interpret Clinical Data.” Presented by Dr. Thomas Wakefield. VEITH Symposium 2015, November 17-21, 2015, New York, NY. |
19. Zhang JY, Briski R, Devata S, Kaminski MS, Phillips T, Mayer T, Bailey NG, Wilcox RA. Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL). Poster presentation at the 58th American Society of Hematology Annual Meeting and Exposition, December 2-6, 2016, San Diego, CA. |
20. Angelini DE, Devata S, Hawley A, Blackburn S, Satwinder G, Hemmer MV, Flanner H, Kramer W, Parker WE, Li YL, Myers DD, Froehlich J, Magnani JL, Thackray HM, Wakefield TW, Sood SL. E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers. Poster presentation at the 58th American Society of Hematology Annual Meeting and Exposition, December 2-6, 2016, San Diego, CA. |
21. Shango M, Devata S, Wilcox RA, Phillips TJ. Clinical Applications of Genetic Sequencing in Lymphoma: A Retrospective Review. J Clin Oncol (Meeting Abstracts) 2017; 35:e23169. |
22. Ramchandren R, Phillips TJ, Devata S, et al. A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma. Poster presentation at the 59th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2017, Atlanta, GA. |
23. Hu N, Wang F, Bernard D, Wang S, Kaminski M, Devata S, et al. Functional Analyses of BTK Mutations in Follicular Lymphoma. Poster presentation at the 59th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2017, Atlanta, GA. |
24. Geer M, Shango M, Till BG, Smith SD, et al. Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States. Oral presentation at the 59th American Society of Hematology Annual Meeting and Exposition, December, 9-12 2017, Atlanta, GA. |
25. Yasuhiro O, Zain J, Haverkos BM, et al. Safety and Anti-Tumor Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an Ongoing Phase I/Ib Study. Poster presentation at the 59th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2017, Atlanta, GA. |
26. Silk AW, LeBoeuf NR, Rabinowits G, Puzanov I, Burgess MA, Devata S, et al. A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). J Clin Oncol 2018; 36(5_suppl):TPS219-TPS219. |
27. Yasuhiro O, Haverkos B, Zain JM, Lechowicz MJ, Devata S, et al. Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma. J Clin Oncol 2018; 36(15_suppl):7510-7510. |
28. Huen A, Ferreri AJ, Haverkos B, Zain JM, Lechowicz MJ, Devata S, et al. Pooled Safety Analysis and efficacy of Tenalisib (RP6530), a dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies. Poster presentation at the 60th American Society of Hematology Annual Meeting and Exposition, December 1-4, 2018, San Diego, CA. |
29. Merrill SA, Bockenstedt PL, Campagnaro EL, Devata S, et al. Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study. Poster presentation at the 60th American Society of Hematology Annual Meeting and Exposition, December 1-4, 2018, San Diego, CA. |
30. Bartlett N, Chen RW, Domingo-Domenech E, Forero-Torres A, et al. A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. Poster presentation at the 60th American Society of Hematology Annual Meeting and Exposition, December 1-4, 2018, San Diego, CA. |
31. Iyre SP, Haverkos BM, Zain J, Ramchandren R, Lechowicz MJ, Devata S, Korman N, Pinter-Brown LC, et al. Final results of Phase 1/1b Study of Tenalisib, Dual PI3K delta/gamma, inhibitor in Patients with Relapsed/Refractory T-cell lymphoma. Poster presentation at the 61st American Society of Hematology Annual Meeting and Exposition, December 6-10, Orlando, FL. |
32. Villasboas JC, Reeder CB, Tun HW, Bartlett NL, Sharon E, Laplant B, Adjei AA, Kline K, et al. The DIAL Study (Dual immunomodulation in Aggressive Lymphoma): A randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas. Poster presentation at the 61st American Society of Hematology Annual Meeting and Exposition, December 6-10, Orlando, FL. |
33. Hou JZ, Jacobs R, Yoon DH, Cho SG, Devata S, Gaballa S, et al. Interim results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapse/Refractory (R/R) B-NHL. Oral presentation at the 64th American Society of Hematology Annual Meeting and Exposition, December 9-13, 2022, New Orleans, LA. |
34. Nair R, Jacobs R, Cho S, Devata S, Gaballa S, Yoon DH, et al. High Complete Response Rate with TNB-486 in Relapsed/Refractory Follicular Lymphoma: Interim Results from an Ongoing Phase 1 Study. Poster presentation at the 59th American Society of Clinical Oncology, June 2-6, 2023, Chicago, IL. |
35. Shah N, Szabo A, Rajguru S, Devata S, Howard M, et al. Phase II trial of split-dose R- CHOP for older patients with diffuse large B-cell lymphoma (DLBCL). Poster presentation at the 59th American Society of Clinical Oncology, June 2-6, 2023, Chicago, IL. |
36. Jacobs R, Nair R, Cho S, Devata S, Gaballa S, Yoon DH, Stevens D, et al. High Complete Response Rate with TNB-486, a Novel CD19xCD3 T-cell Engager (TCE), in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Interim Results from an Ongoing Phase I Study. Presentation at the 28th European Hematology Association Congress, June 8-11, 2023, Frankfurt, Germany. |
37. Cho S, Nair R, Jacobs R, Devata S, Gaballa S, Yoon DH, et al. High Complete Response Rate With TNB-486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Follicular Lymphoma: Interim Results from an Ongoing Phase 1 Study. Presentation at the 17th International Conference on Malignant Hematology, June 13 -17, 2023, Lugano, Switzerland. |
38. Nair R, Jacobs R, Cho S, Devata S, Gaballa S, Yoon DH, Stevens D, et al. High Complete Response Rate with TNB-486 in Relapsed/Refractory Follicular Lymphoma: Interim Results from an Ongoing Phase 1 Study. Poster presentation at the 2nd Bermuda Translational Summit on Hematologic Malignancies, DAVA Oncology, July 27-30, 2023, Burmuda. |
39. Gaballa S, Nair R, Jacobs R, Devata S, Cho, S, Stevens D, et al. Double step-up dosing (2SUD) regimen mitigates severe ICANS and CRS while maintaining high efficacy in subjects with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) treated with AZD0486, a novel CD19xCD3 T-cell engager (TCE): updated safety and efficacy data from the ongoing first-in-human (FIH) phase 1 trial. Poster presentation at the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, San Diego, CA. |
40. Devata S, Gaballa S, Nair R, Cho S, Jacobs R, Yoon D, Stevens D, et al. AZD0486, a Novel CD19xCD3 T-cell Engager, Shows Durable Responses in Patients with Relapsed/Refractory Follicular Lymphoma: Update on Efficacy and Safety. Accepted for poster presentation at the 29th European Hematology Association Congress, June 13-16, 2024, Madrid, Spain. |
Peer Reviewed Educational Products |
1. Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel). 2020 Aug 15;12(8). PMCID: PMC7463651 |
2. Prechel MM, Halbur L, Devata S, Vaidya AM, Young MR. Increased interleukin-6 production by cerebral cortical tissue of adult versus young mice. Mech Ageing Dev. 1996;92(2-3): 185-94. PMID: 9080398. |
3. Scott AJ, Tokaz MC, Shango M, Devata S, Carty SA, Kaminski MS, Chinnaiyan AM, Phillips TJ, Wilcox RA. Clinical application of next generation sequencing in lymphoma. Leuk Lymphoma. 2021 Apr;62(4):868-873. |
4. Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D, Xu S, Wang S, Kaminski M, Devata S, Phillips T, Malek SN. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clin Cancer Res. 2021 Apr 15;27(8):2301-2313. PMCID: PMC8046715 |
5. Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D, Xu S, Wang S, Kaminski M, Devata S, Phillips T, Malek SN. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clin Cancer Res. 2021 Apr 15;27(8):2301-2313. PMCID: PMC8046715 |
6. Singh V, Devata S, Cheng Y. Carboplatin and Docetaxel Induced Acute Pancreatitis: Brief Report. Int J Clin Oncol. 2010;15(6):642-4. PMID: 20602134. |
7. Shidham V, Hunt B, Safwan J, Barboi A, Devata S, Hari P. Performing and Processing FNA of Anterior Fat Pad for Amyloid. J Vis Exp. 2010;(44). PMID: 21085098. |
8. Geer MJ, Foucar CE, Devata S, Benitez L, Perissinotti AJ, Marini BL, Bixby D. Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed. J Natl Compr Canc Netw. 2021 Aug 17;19(11):1272-1275. |
9. Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. 2022 May 25;12(5):82. PMCID: PMC9132975 |
10. Devata S, Hari P, Markelova N, Li R, Komorowski R, and Shidham V. Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. CytoJournal. 2011;8:11. PMID: 21760829. |
11. Devata S, Kim E. Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor. Case Rep Oncol. 2012;5(3): 622-6. PMID: 23275776 |
12. Devata S, Wilcox RA. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Am J Clin Dermatol. 2016;17(3):225-237. PMID: 26923912. |
13. Grivas PD*, Devata S*, Khoriaty R, Boonstra PS, et al. Low-cost intervention to increase influenza vaccination rate at a Comprehensive Cancer Center. J Canc Ed. 2016; April 7 (Epub ahead of print). PMID: 27055536. *Designates co-first authors. |
14. Phillips T, Devata S, Wilcox RA. Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. J Immunother Cancer. 2016; 4:95. PMID: 28031823. |
15. Boonstra PS, Polk A, Brown N, Hristov AC, Bailey NG, Kaminski MS, Phillips T, Devata S, Mayer T, Wilcox RA. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas. Am J Hematol. 2017;92(12):1287-1294. PMID: 28842936. |
16. Murga-Zamalloa C, Polk A, Hanel W, Chowdhury P, Brown N, Hristov AC, Bailey NG, Wang T, Phillips T, Devata S, Poonnen P, Gomez-Gelvez J, Inamdar KV, Wilcox RA. Polo-like kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget. 2017;8(70):114474-114480. PMID: 29383095. |
17. Zhang JY, Briski R, Devata S, Kaminski MS, Phillips TJ, Mayer TL, Bailey NG, Wilcox RA. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2018;93(3):394-400. PMID: 29194714. |
18. Geer M, Roberts E, Shango M, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum R, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol. 2019;186(2):255-262. PMID 31044423. |
19. Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, Gitlin SD, Kaminski M, et al. Ruxolitinib in adult patients with secondary haemophagoctic lymphohistiocytosis: an open-label, single-centre, pilot trial. The Lancet Haematology. 2019;6(12);e630-e637. PMID: 31537486. |
20. Girard J, Reneau J, Devata S, Wilcox RA, et al. Evaluating Acalabrutinib In The Treatment of Mantle Cell Lymphoma: Design, Development, and Place in Therapy. Onco Targets Ther. 2019;12:8003-8014. PMID: 31686856. |
21. Reid JH, Marini BL, Nachar VR, Devata S, Perissinotti AJ. PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. Lancet Oncol. 2019;20(4):e188. PMID: 30942175. |
22. Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Crit Rev Oncol Hematol. 2020;148:102897. PMID: 32109715. |
23. Weis TM, Marini BL, Nachar VR, Brown AM, Phillips TJ, Brown J, Wilcox RA, Kaminski MS, Devata S, Perissinotti AJ. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Leuk Lymphoma. 2020;61(5):1126-1132. PMID: 31876206. |
24. Devata S*, Angelini DE*, Blackburn S, Hawley A, et al. Use of GMI-1271, an E-selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis. Res Pract Thromb Haemost. 2020;4(2):193‐204. PMID: 32110749. *Designates co-first authors. |
25. Huen A, Haverkos BM, Zain J, Ramchandren R, Lechowica MJ, Devata S, et al. Phase I/Ib study of Tenalisib (RP6530), a Dual PI3K δ/γ inhibitor in patients with relapsed/refractory T-cell lymphoma. Cancers. 2020;12(8):2293. PMID: 32824175. |
Non-Peer Reviewed Educational Products |
1. Devata, S. New FISH Probes Enhance Cancer Patient Management. Oncologistics Magazine 2002; Fourth Quarter: 24-25 |
2. Gorshein E, Devata S. Immunotherapy Emerges as Treatment for T-Cell Lymphoma. ASCO-SITC Clinical Immuno Oncology Symposium Daily News 2018: Online 2018. |
